世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Rapid Influenza Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global rapid influenza diagnostic tests market is undergoing a substantial transformation, driven by a heightened focus on respiratory health, innovations in molecular diagnostics, and increasi... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global rapid influenza diagnostic tests market is undergoing a substantial transformation, driven by a heightened focus on respiratory health, innovations in molecular diagnostics, and increasing preference for convenient and accurate point-of-care testing solutions. According to new industry analysis, the market is projected to grow from US$ 970 million in 2025 to approximately US$ 1.8 billion by the end of 2032, expanding at a robust CAGR of 9.23% during the forecast period.Market Insights With influenza remaining a major global health concern, the need for accurate and rapid diagnostic methods has intensified. Traditional diagnostics are increasingly complemented by molecular and digital platforms that offer higher sensitivity and faster results. The emergence of multiplex testing platforms and self-testing kits is redefining the market Analysis, catering to both clinical and home care environments. Recent innovations such as Roche’s cobas® Respiratory flex test and Lucira’s FDA-approved home testing kits underscore the market’s pivot toward flexible, multi-pathogen, and user-friendly diagnostics. These solutions allow the detection of up to 12 respiratory viruses in a single test, enhancing diagnostic efficiency while reducing time to treatment. Market Drivers Technological progress is a key driver propelling the growth of the rapid influenza diagnostic tests market. Modern molecular platforms, including nucleic acid amplification tests (NAATs), offer improved accuracy and faster turnaround. For instance, Abbott’s ID NOW™ platform provides molecular influenza results within minutes, significantly enhancing point-of-care decision-making. Moreover, the COVID-19 pandemic has accelerated awareness around respiratory illnesses and amplified public and institutional demand for early and precise influenza detection. Advancements in digital immunoassays, like BD’s Veritor™ Plus System, are improving interpretation accuracy by minimizing human error, further boosting adoption in clinical settings. Business Opportunity The shift toward over-the-counter (OTC) and home-based testing presents a major growth opportunity. Regulatory bodies are showing increased support for self-testing solutions. The FDA’s approval of the Lucira COVID-19 & Flu Home Test demonstrates this trend. These kits allow consumers to test for influenza A, B, and COVID-19 from the comfort of their homes, promoting early detection, reducing transmission, and relieving healthcare system burdens. Manufacturers that invest in user-friendly, compact, and affordable diagnostic kits for home use stand to gain significant market share. The integration of digital platforms and mobile app connectivity for result interpretation further enhances consumer appeal and market reach. Regional Analysis North America is set to dominate the global rapid influenza diagnostic tests market, projected to account for approximately 38.4% of the market in 2025. The region benefits from strong regulatory frameworks, a high adoption rate of innovative diagnostics, and frequent influenza outbreaks. Asia Pacific, particularly East Asia, is emerging as a fast-growing market due to increasing disease surveillance initiatives and rapid investments in healthcare infrastructure. Japan and China are witnessing a surge in demand for high-throughput influenza diagnostic solutions, supported by government-led healthcare reforms and public health strategies. Key Players The competitive Analysis is characterized by rapid innovation and strategic expansions. Key players include: • F. Hoffmann-La Roche Ltd • Abbott • QuidelOrtho Corporation • BD (Becton, Dickinson and Company) • Thermo Fisher Scientific Inc. • DiaSorin S.p.A. • SEKISUI Diagnostics • Kaneka Corporation • Virax Biolabs • iHealth Labs Inc. These companies are focusing on portfolio expansion, regulatory approvals, and strategic collaborations to maintain market leadership. For instance, SEKISUI’s OSOM Flu SARS-CoV-2 Combo Test and Kaneka’s dual antigen test highlight the integration of multi-pathogen detection in a single kit. Market Segmentation By Product Type • Conventional • Digital By Test Type • Influenza A Test • Influenza B Test • Influenza A+B Test By Assay Type • Immunochromatographic Assays • Immunofluorescence Assays • Nucleic Acid Amplification Test (NAAT) By Sample Type • Throat Swab • Nasal Swab • Nasal Aspirate • Nasopharyngeal Swab • Nasopharyngeal Aspirate • Nasopharyngeal Wash By End User • Hospitals & Clinics • Diagnostic Centers & Laboratories • Nursing Homes • Home Care Settings • Others By Region • North America • Europe • East Asia • South Asia and Oceania • Latin America • Middle East and Africa Table of Contents1. Executive Summary1.1. Global Rapid Influenza Diagnostic Tests Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 3.1. Global Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Immunochromatographic Assays 3.1.1.2. Immunofluorescence Assays 3.1.1.3. Nucleic Acid Amplification Test (NAAT) 3.2. Global Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Influenzas A Test 3.2.1.2. Influenza B Test 3.2.1.3. Influenza A+B Test 3.3. Global Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. Throat Swab 3.3.1.2. Nasal Swab 3.3.1.3. Nasal Aspirate 3.3.1.4. Nasal Wash 3.3.1.5. Nasopharyngeal Swab 3.3.1.6. Nasopharyngeal Aspirate 3.3.1.7. Nasopharyngeal Wash 3.3.1.8. Others 3.4. Global Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 3.4.1. Key Highlights 3.4.1.1. Hospitals 3.4.1.2. Diagnostic Centers 3.4.1.3. Nursing Homes 3.4.1.4. Office-based Settings 3.4.1.5. Urgent Care Centers 3.4.1.6. Retail Pharmacy Clinics 3.4.1.7. Schools & Universities 3.4.1.8. Public Health Camps 3.4.1.9. Others 3.5. Global Rapid Influenza Diagnostic Tests Market Outlook, by Region, Value (US$ Mn), 2019-2032 3.5.1. Key Highlights 3.5.1.1. North America 3.5.1.2. Europe 3.5.1.3. Asia Pacific 3.5.1.4. Latin America 3.5.1.5. Middle East & Africa 4. North America Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 4.1. North America Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Immunochromatographic Assays 4.1.1.2. Immunofluorescence Assays 4.1.1.3. Nucleic Acid Amplification Test (NAAT) 4.2. North America Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Influenzas A Test 4.2.1.2. Influenza B Test 4.2.1.3. Influenza A+B Test 4.3. North America Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. Throat Swab 4.3.1.2. Nasal Swab 4.3.1.3. Nasal Aspirate 4.3.1.4. Nasal Wash 4.3.1.5. Nasopharyngeal Swab 4.3.1.6. Nasopharyngeal Aspirate 4.3.1.7. Nasopharyngeal Wash 4.3.1.8. Others 4.4. North America Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 4.4.1. Key Highlights 4.4.1.1. Hospitals 4.4.1.2. Diagnostic Centers 4.4.1.3. Nursing Homes 4.4.1.4. Office-based Settings 4.4.1.5. Urgent Care Centers 4.4.1.6. Retail Pharmacy Clinics 4.4.1.7. Schools & Universities 4.4.1.8. Public Health Camps 4.4.1.9. Others 4.5. North America Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Mn), 2019-2032 4.5.1. Key Highlights 4.5.1.1. U.S. Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 4.5.1.2. U.S. Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 4.5.1.3. U.S. Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 4.5.1.4. U.S. Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 4.5.1.5. Canada Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 4.5.1.6. Canada Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 4.5.1.7. Canada Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 4.5.1.8. Canada Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 4.5.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 5.1. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Immunochromatographic Assays 5.1.1.2. Immunofluorescence Assays 5.1.1.3. Nucleic Acid Amplification Test (NAAT) 5.2. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Influenzas A Test 5.2.1.2. Influenza B Test 5.2.1.3. Influenza A+B Test 5.3. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Throat Swab 5.3.1.2. Nasal Swab 5.3.1.3. Nasal Aspirate 5.3.1.4. Nasal Wash 5.3.1.5. Nasopharyngeal Swab 5.3.1.6. Nasopharyngeal Aspirate 5.3.1.7. Nasopharyngeal Wash 5.3.1.8. Others 5.4. Europe Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 5.4.1. Key Highlights 5.4.1.1. Hospitals 5.4.1.2. Diagnostic Centers 5.4.1.3. Nursing Homes 5.4.1.4. Office-based Settings 5.4.1.5. Urgent Care Centers 5.4.1.6. Retail Pharmacy Clinics 5.4.1.7. Schools & Universities 5.4.1.8. Public Health Camps 5.4.1.9. Others 5.5. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Mn), 2019-2032 5.5.1. Key Highlights 5.5.1.1. Germany Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.2. Germany Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.3. Germany Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.4. Germany Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.5. U.K. Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.6. U.K. Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.7. U.K. Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.8. U.K. Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.9. France Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.10. France Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.11. France Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.12. France Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.13. Italy Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.14. Italy Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.15. Italy Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.16. Italy Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.17. Turkey Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.18. Turkey Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.19. Turkey Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.20. Turkey Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.21. Russia Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.22. Russia Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.23. Russia Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.24. Russia Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.1.25. Rest of Europe Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 5.5.1.26. Rest of Europe Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 5.5.1.27. Rest of Europe Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 5.5.1.28. Rest of Europe Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 5.5.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 6.1. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Immunochromatographic Assays 6.1.1.2. Immunofluorescence Assays 6.1.1.3. Nucleic Acid Amplification Test (NAAT) 6.2. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Influenzas A Test 6.2.1.2. Influenza B Test 6.2.1.3. Influenza A+B Test 6.3. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. Throat Swab 6.3.1.2. Nasal Swab 6.3.1.3. Nasal Aspirate 6.3.1.4. Nasal Wash 6.3.1.5. Nasopharyngeal Swab 6.3.1.6. Nasopharyngeal Aspirate 6.3.1.7. Nasopharyngeal Wash 6.3.1.8. Others 6.4. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 6.4.1. Key Highlights 6.4.1.1. Hospitals 6.4.1.2. Diagnostic Centers 6.4.1.3. Nursing Homes 6.4.1.4. Office-based Settings 6.4.1.5. Urgent Care Centers 6.4.1.6. Retail Pharmacy Clinics 6.4.1.7. Schools & Universities 6.4.1.8. Public Health Camps 6.4.1.9. Others 6.5. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Mn), 2019-2032 6.5.1. Key Highlights 6.5.1.1. China Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.2. China Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.3. China Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.4. China Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.1.5. Japan Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.6. Japan Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.7. Japan Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.8. Japan Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.1.9. South Korea Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.10. South Korea Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.11. South Korea Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.12. South Korea Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.1.13. India Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.14. India Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.15. India Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.16. India Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.1.17. Southeast Asia Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.18. Southeast Asia Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.19. Southeast Asia Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.20. Southeast Asia Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.1.21. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 6.5.1.22. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 6.5.1.23. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 6.5.1.24. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 6.5.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 7.1. Global Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Immunochromatographic Assays 7.1.1.2. Immunofluorescence Assays 7.1.1.3. Nucleic Acid Amplification Test (NAAT) 7.2. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Influenzas A Test 7.2.1.2. Influenza B Test 7.2.1.3. Influenza A+B Test 7.3. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Throat Swab 7.3.1.2. Nasal Swab 7.3.1.3. Nasal Aspirate 7.3.1.4. Nasal Wash 7.3.1.5. Nasopharyngeal Swab 7.3.1.6. Nasopharyngeal Aspirate 7.3.1.7. Nasopharyngeal Wash 7.3.1.8. Others 7.4. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 7.4.1. Key Highlights 7.4.1.1. Hospitals 7.4.1.2. Diagnostic Centers 7.4.1.3. Nursing Homes 7.4.1.4. Office-based Settings 7.4.1.5. Urgent Care Centers 7.4.1.6. Retail Pharmacy Clinics 7.4.1.7. Schools & Universities 7.4.1.8. Public Health Camps 7.4.1.9. Others 7.5. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Mn), 2019-2032 7.5.1. Key Highlights 7.5.1.1. Brazil Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 7.5.1.2. Brazil Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 7.5.1.3. Brazil Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 7.5.1.4. Brazil Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 7.5.1.5. Mexico Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 7.5.1.6. Mexico Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 7.5.1.7. Mexico Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 7.5.1.8. Mexico Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 7.5.1.9. Argentina Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 7.5.1.10. Argentina Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 7.5.1.11. Argentina Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 7.5.1.12. Argentina Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 7.5.1.13. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 7.5.1.14. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 7.5.1.15. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 7.5.1.16. Rest of Latin America Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 7.5.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, 2019-2032 8.1. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Mn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Immunochromatographic Assays 8.1.1.2. Immunofluorescence Assays 8.1.1.3. Nucleic Acid Amplification Test (NAAT) 8.2. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Mn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Influenzas A Test 8.2.1.2. Influenza B Test 8.2.1.3. Influenza A+B Test 8.3. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Mn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. Throat Swab 8.3.1.2. Nasal Swab 8.3.1.3. Nasal Aspirate 8.3.1.4. Nasal Wash 8.3.1.5. Nasopharyngeal Swab 8.3.1.6. Nasopharyngeal Aspirate 8.3.1.7. Nasopharyngeal Wash 8.3.1.8. Others 8.4. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Mn), 2019-2032 8.4.1. Key Highlights 8.4.1.1. Hospitals 8.4.1.2. Diagnostic Centers 8.4.1.3. Nursing Homes 8.4.1.4. Office-based Settings 8.4.1.5. Urgent Care Centers 8.4.1.6. Retail Pharmacy Clinics 8.4.1.7. Schools & Universities 8.4.1.8. Public Health Camps 8.4.1.9. Others 8.5. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Mn), 2019-2032 8.5.1. Key Highlights 8.5.1.1. GCC Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 8.5.1.2. GCC Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 8.5.1.3. GCC Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 8.5.1.4. GCC Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 8.5.1.5. South Africa Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 8.5.1.6. South Africa Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 8.5.1.7. South Africa Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 8.5.1.8. South Africa Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 8.5.1.9. Egypt Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 8.5.1.10. Egypt Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 8.5.1.11. Egypt Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 8.5.1.12. Egypt Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 8.5.1.13. Nigeria Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 8.5.1.14. Nigeria Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 8.5.1.15. Nigeria Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 8.5.1.16. Nigeria Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 8.5.1.17. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Mn), 2019-2032 8.5.1.18. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Mn), 2019-2032 8.5.1.19. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Mn), 2019-2032 8.5.1.20. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Mn), 2019-2032 8.5.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. by Sample Type vs by Test Type Heatmap 9.2. Manufacturer vs by Test Type Heatmap 9.3. Company Market Share Analysis, 2025 9.4. Competitive Dashboard 9.5. Company Profiles 9.5.1. Thermo Fisher Scientific Inc 9.5.1.1. Company Overview 9.5.1.2. Product Portfolio 9.5.1.3. Financial Overview 9.5.1.4. Business Strategies and Development 9.5.2. Hologic 9.5.2.1. Company Overview 9.5.2.2. Product Portfolio 9.5.2.3. Financial Overview 9.5.2.4. Business Strategies and Development 9.5.3. Quidel Corporation 9.5.3.1. Company Overview 9.5.3.2. Product Portfolio 9.5.3.3. Financial Overview 9.5.3.4. Business Strategies and Development 9.5.4. F. Hoffmann-La Roche AG 9.5.4.1. Company Overview 9.5.4.2. Product Portfolio 9.5.4.3. Financial Overview 9.5.4.4. Business Strategies and Development 9.5.5. Abbott Laboratories 9.5.5.1. Company Overview 9.5.5.2. Product Portfolio 9.5.5.3. Financial Overview 9.5.5.4. Business Strategies and Development 9.5.6. Becton Dickinson and Company 9.5.6.1. Company Overview 9.5.6.2. Product Portfolio 9.5.6.3. Financial Overview 9.5.6.4. Business Strategies and Development 9.5.7. Danaher Corporation 9.5.7.1. Company Overview 9.5.7.2. Product Portfolio 9.5.7.3. Financial Overview 9.5.7.4. Business Strategies and Development 9.5.8. Meridian Bioscience 9.5.8.1. Company Overview 9.5.8.2. Product Portfolio 9.5.8.3. Financial Overview 9.5.8.4. Business Strategies and Development 9.5.9. bioMérieux SA 9.5.9.1. Company Overview 9.5.9.2. Product Portfolio 9.5.9.3. Financial Overview 9.5.9.4. Business Strategies and Development 9.5.10. Luminex Corporation 9.5.10.1. Company Overview 9.5.10.2. Product Portfolio 9.5.10.3. Financial Overview 9.5.10.4. Business Strategies and Development 9.5.11. Siemens Healthineers AG 9.5.11.1. Company Overview 9.5.11.2. Product Portfolio 9.5.11.3. Financial Overview 9.5.11.4. Business Strategies and Development 9.5.12. GenMark Diagnostics 9.5.12.1. Company Overview 9.5.12.2. Product Portfolio 9.5.12.3. Financial Overview 9.5.12.4. Business Strategies and Development 9.5.13. Sekisui Diagnostics 9.5.13.1. Company Overview 9.5.13.2. Product Portfolio 9.5.13.3. Financial Overview 9.5.13.4. Business Strategies and Development 9.5.14. LLC altona Diagnostics GmbH 9.5.14.1. Company Overview 9.5.14.2. Product Portfolio 9.5.14.3. Financial Overview 9.5.14.4. Business Strategies and Development 9.5.15. SA Scientific 9.5.15.1. Company Overview 9.5.15.2. Product Portfolio 9.5.15.3. Financial Overview 9.5.15.4. Business Strategies and Development 9.5.16. ELITech Group 9.5.16.1. Company Overview 9.5.16.2. Product Portfolio 9.5.16.3. Financial Overview 9.5.16.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（diagnostic）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
